Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PLK1 | P53350 | 1/20 | 0.31 |
| ▸ | TOP2A | P11388 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL641370 | 0.77 | P2RX7 (0.39) | P2RX7 | |
| SCHEMBL16791178 | 0.76 | P2RX7 (0.35) | P2RX7 | |
| SCHEMBL9883093 | 0.75 | P2RX7 (0.38) | P2RX7 | |
| SCHEMBL6450016 | 0.75 | P2RX7 (0.54) | P2RX7 | |
| SCHEMBL7309773 | 0.75 | P2RX7 (0.34) | P2RX7 | |
| SCHEMBL6428553 | 0.73 | ALDH1A1 (0.50) | TOP2A | |
| SCHEMBL15588816 | 0.71 | P2RX7 (0.40) | P2RX7 | |
| SCHEMBL14026712 | 0.70 | — | — | |
| SCHEMBL2363536 | 0.70 | P2RX7 (0.60) | P2RX7POLBTDP1PLK1 | |
| SCHEMBL1688461 | 0.70 | P2RX7 (0.38) | P2RX7TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960562-B2 | Propane-1,3-dione derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7960562-B2 | Propane-1,3-dione derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090181964-A1 | Propane-1,3-Dione Derivative or Salt Thereof | ASTELLAS PHARMA INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090181964-A1 | Propane-1,3-Dione Derivative or Salt Thereof | ASTELLAS PHARMA INC. | 2009-07-16 | — | — | US | disclosed |
| US-20080260633-A1 | Having light absorbing metal cores, electron accumulator ligand and catalytically active metal; when exposured to radiant energy; forming charge transfer compounds; reduction of water to hydrogen | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2008-10-23 | — | — | US | disclosed |
| EP-1864976-A1 | PROPANE-1,3-DION DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181964-A1 | Propane-1,3-Dione Derivative or Salt Thereof | GNRHR, KISS1R, FSHR | P2RX7 2031/4885POLB 4073/4885TDP1 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.